Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment
IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentationMARSEILLE, France (BUSINESS WIRE) #ANKET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) tod.